From Yahoo Finance: 2025-05-10 11:55:00

• Biotech stocks experiencing a surge in search interest include Galmed Pharmaceuticals (GLMD), Protagenic Therapeutics (PTIX), Hepion Pharmaceuticals (HEPA), Rigel Pharmaceuticals (RIGL), Bolt Biotherapeutics (BOLT), Palatin Technologies (PTN), Krystal Biotech (KRYS), CorMedix (CRMD), Bio-Techne Corporation (TECH), and Jazz Pharmaceuticals (JAZZ).
• Galmed focuses on Aramchol for liver and fibro-inflammatory diseases. Protagenic works on neuro-active peptides for stress disorders. Hepion is developing treatments for liver diseases. Rigel specializes in therapies for hematologic disorders and cancer. Bolt is focused on cancer immunotherapies. Palatin develops melanocortin receptor system-based medicines. Krystal Biotech works on genetic medicines for diseases. CorMedix focuses on therapeutic products for life-threatening conditions. Bio-Techne provides tools for research and diagnostics. Jazz develops medicines for serious diseases.
• Recent news includes Palatin’s preclinical data on melanocortin agonists, Bolt hosting a conference call on clinical study results, Hepion in-licensing diagnostic tests, Bio-Techne’s Q3 earnings, Galmed’s oncology studies showing Aramchol’s effectiveness, Rigel’s upbeat Q1 results, and Jazz’s Q1 results and revised earnings outlook.
• Truist raised CorMedix’s price target and maintains a Buy rating due to solid Q1 results. Jazz reported downbeat Q1 results but is affirming its total revenue guidance for 2025.

  This news highlights the increased interest in biotech stocks and recent developments in the sector.

Read more: Searches spiking for these stocks today